The pharmaceutical and life science industries have experienced unique challenges over the course of the pandemic, requiring a critical need for flexibility and collaboration amongst all stakeholders throughout the clinical trial ecosystem. The industry’s shift into the “new normal” will call for innovative solutions, effective risk mitigation and advanced technological tools that reimagine the integrated value chain.
In this complimentary webinar, expert speakers will discuss current operational obstacles and explore strategic solutions to optimize a supply chain strategy in the years ahead.
Register for this webinar to learn about:
- Risk assessment and mitigation: How can we be better prepared for another pandemic in the future?
- The essential need for technology integration and interoperability for the emerging virtual trial landscape
- The importance of choosing a flexible supply chain partner that enables you to accommodate both traditional and decentralized trial models now and in a post-pandemic world
Speakers
Dan Bell, Senior Vice President, Americas Region, Marken
Dan Bell joined Marken in 2003 and is Senior Vice President, Americas Region. Dan is a licensed US Customs Broker and a Certified Customs Specialist with 25+ years of experience in the life science logistics & temperature control field. His current focus is regulatory and trade compliance aspects for global life science supply chain solutions. Dan has served as a liaison between his clients, customs and the alphabet soup of regulatory agencies to ensure the maximum level of compliance with trade laws and regulations.
His knowledge and experience in this arena have led to the development of many import strategies that have significantly reduced turn-around times, optimized cost and ensured that mission-critical objectives have been met or exceeded. As regulatory scrutiny continues to focus on the temperature-controlled supply chain, Dan’s expertise with thermo-regulating packaging solutions and temperature-logging devices has been critical to meeting the requirements of the recently updated Good Distribution Practices for pharmaceutical transport and similar guidelines.
Message Presenter
Kimberly Finn, Vice President, Global Patient Centric Services, Marken
Kim has extensive experience in the clinical trials industry with over 25 years’ experience in roles within clinical operations and global project management in both pharma and CRO organizations. Kim’s expertise in protocol design and clinical strategy has contributed to successful, on-time delivery of complex portfolios, and she has directly contributed to the development of many New Drug Application (NDA) approved and marketed compounds.
Message PresenterWho Should Attend?
Senior professionals who are involved with:
- Pharmaceutical Companies
- Biotechnology Companies
- Central Labs
- CMOs
- CROs
- CDMOs
What You Will Learn
In this webinar, participants will learn about:
- Year in Review/Lessons Learned
- Agile solutions to support a flexible supply chain
- Industry shift: critical need for cooperation and collaboration among all key players
- Risk assessment and mitigation: How can we be better prepared for another pandemic in the future?
- Looking Ahead/What to Expect in 2022-2023 & Beyond
- The new business model that emerged will require accelerated and scalable clinical trial readiness
- Essential need for technology integration and interoperability for the emerging virtual trial landscape
- Importance of choosing a flexible supply chain partner that enables you to accommodate both traditional and decentralized trial models now and in a post-pandemic world
Xtalks Partner
Marken
Marken is a wholly owned subsidiary of UPS and is a critical part of UPS Healthcare. With Polar Speed and Marken included, the UPS Healthcare division staffs 128 locations with 5,500 employees worldwide. Marken offers a state-of-the-art GMP-compliant depot network and logistic hubs for clinical drug product storage and distribution in 58 locations worldwide, while maintaining the leading position for Direct-to-Patient and Home Healthcare services, biological sample shipments and biological kit production. Marken’s dedicated 1,900 staff members manage 120,000 drug product and biological sample shipments every month at all temperature ranges in more than 220 countries. Additional services such as ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
Related Webinars
Transformative Future of ATMPs: Healthcare Reimagined
Innovation Driving the Future of Vaccine Development and Distribution
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account